386 related articles for article (PubMed ID: 33211076)
1. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
Bressler NM; Kim T; Oh I; Russo P; Kim MY; Woo SJ
JAMA Ophthalmol; 2023 Feb; 141(2):117-127. PubMed ID: 36520462
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
Woo SJ; Bradvica M; Vajas A; Sagong M; Ernest J; Studnicka J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Kim T; Oh I; Jang H; Sadda SR
JAMA Ophthalmol; 2023 Jul; 141(7):668-676. PubMed ID: 37289448
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Bressler NM; Veith M; Hamouz J; Ernest J; Zalewski D; Studnička J; Vajas A; Papp A; Vogt G; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Oh I; Jeong H; Kim MY; Woo SJ
Br J Ophthalmol; 2023 Mar; 107(3):384-391. PubMed ID: 34656987
[TBL] [Abstract][Full Text] [Related]
6. Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Loewenstein A; Czumbel N; Ernest J; Dusová J; Pearlman J; Nowosielska A
Ophthalmol Retina; 2023 Sep; 7(9):753-761. PubMed ID: 37179017
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
Kertes PJ; Galic IJ; Greve M; Williams G; Baker J; Lahaie M; Sheidow T
JAMA Ophthalmol; 2020 Mar; 138(3):244-250. PubMed ID: 31917441
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
9. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
Staurenghi G; Garweg JG; Gerendas BS; Macfadden W; Gekkiev B; Margaron P; Dunger-Baldauf C; Kolar P
BMC Ophthalmol; 2020 Jan; 20(1):18. PubMed ID: 31918685
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial.
Yoon CK; Oh J; Bae K; Park UC; Yu KS; Yu HG
PLoS One; 2022; 17(11):e0275611. PubMed ID: 36374913
[TBL] [Abstract][Full Text] [Related]
11. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
12. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
Callanan D; Kunimoto D; Maturi RK; Patel SS; Staurenghi G; Wolf S; Cheetham JK; Hohman TC; Kim K; López FJ; Schneider S
J Ocul Pharmacol Ther; 2018 Dec; 34(10):700-709. PubMed ID: 30412448
[No Abstract] [Full Text] [Related]
13. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
15. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C;
Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713
[TBL] [Abstract][Full Text] [Related]
16. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
Ramakrishnan MS; Yu Y; VanderBeek BL
JAMA Ophthalmol; 2020 Mar; 138(3):237-242. PubMed ID: 32027349
[TBL] [Abstract][Full Text] [Related]
17. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
Scoles D; Ying GS; Pan W; Hua P; Grunwald JE; Daniel E; Jaffe GJ; Toth CA; Martin DF; Maguire MG;
JAMA Ophthalmol; 2020 Mar; 138(3):276-284. PubMed ID: 31999297
[TBL] [Abstract][Full Text] [Related]
19. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
[TBL] [Abstract][Full Text] [Related]
20. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
